# Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer

> **NCT00428766** · PHASE1 · COMPLETED · sponsor: **Morphotek** · enrollment: 24 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** MORAb-003

## Key facts

- **NCT ID:** NCT00428766
- **Lead sponsor:** Morphotek
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2013-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00428766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00428766, "Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00428766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*